Patients in the vancomycin group also demonstrated reduced readmission rates within 8 weeks following discharge compared with those in the fidaxomicin group (14.6% vs 18.5%, respectively; P ...

In the fidaxomicin and vancomycin groups, adverse gastrointestinal effects were the most common adverse effects reported (25% versus 22.3%, respectively), followed by general disorders (fevers ...

With fidaxomicin, median TTROD was not significantly affected by presence of cancer (74 v 54 hours; log-rank P = .145). In the full mITT population, age, hypoalbuminemia, and cancer were inversely ...

Overall utilization of fidaxomicin remained low and most of the 27.7 percentage point decline in metronidazole shifted to vancomycin (P < .001). Clinical outcomes from the preguideline period to ...

“In the base case, FID-VAN had only a 0.4% likelihood of being cost effective versus VAN-FID at a £20,000 ($25,494) per QALY gained threshold, and a 2.3% likelihood at a £30,000 ($38,241) per ...

Previously, vancomycin and metronidazole had been the recommended first-line agents. The study found an increased use of fidaxomicin from 5.9% in January 2020 to June 2021 to 13.7% between October ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their ...

Am J Health Syst Pharm. 2012;69(11):933-943. Based on current clinical trials reporting fewer recurrences among patients treated with fidaxomicin in which the non-NAP1/BI/027 strains were isolated ...